Noga Therapeutics Ltd.

noga-tx.com

High-Tech Company

TECH VERTICALS

Bioinformatics, Biotechnology, Gene Therapy, Life Sciences, MedTech, Parkinson, Synthetic Biology

General Data

Sector	Biomed
Company Stage:	R&D
Established	2019
Number of Employees	8
Reg. Number:	abCDe

DESCRIPTION

Noga Therapeutics is an operator of a clinical-stage biopharmaceutical platform, intended to accelerate the development of lentiviral gene therapies. The company's platform harnesses the power of synthetic biology and bioinformatics to design optimized lentiviral vectors and give rise to a functional immune system, enabling scientists and physicians to generate a pipeline of lentiviral therapies for the benefit of patients with rare genetic diseases.

TECHNOLOGY

Noga Therapeutics is a gene therapy company, leveraging the power of Lentiviral vectors to cure rare and common diseases.

Products and Phases

Product	Phase
DopaGene™	Phase II
Noga is developing DopaGene™, a novel gene-therapy-based solution for direct dopamine production in the brain. In a single, non-invasive procedure, Parkinson’s disease patient’s own blood stem cells are engineered with DopaGene™ and then re-infused into the bloodstream. Macrophages that develop from the engineered stem cells migrate to the brain, where they settle and produce safe and effective levels of dopamine for years to come. Local dopamine production eliminates the harsh side-effects of dopamine replacement-based products.
BTK-001	Phase I
BTK-001 is a lentiviral vector-based gene therapy designed to re-engineer XLA patient’s own stem cells by delivering the BTK gene directly to stem cells. Upon stem-cell reprograming, patients regain the ability to develop B-cells and produce antibodies, essentially being cured from the disease after a single treatment.

	TARGET MARKETS
	Patients with Parkinson's disease and other neurological diseases and XLA, scientists, physicians

	BUSINESS MODEL
	B2B

COMPETITORS

Biogen , Biontech , Series Therapeutics

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Accounting Firm

CONTACT INFO

Expand / Collapse All

Main Address: Ness Ziona, Israel

Address	3 Pinhas Sapir St., 2nd Floor
City	Ness Ziona
Country	Israel
Zip	7403626

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Noam Baumatz	CEO & Co-Founder
Dr. Rafi Emmanuel	CTO
Mr. Sefi Golan	President & Co-Founder
Dr. Liron Elkouby	Scientific Co-Founder
Dr. Noam Diamant	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Managing Partner & Founder, Medexplore Ventures
abC Defghij	Board Member	President & Co-Founder, Noga Therapeutics
abC Defghij	Board Member	Chief Commercial & Technology Officer, Minaris Advanced Therapies
abC Defghij	Board Member	Managing Director, Smarter City Solutions
abC Defghij	Board Member	CEO & Co-Founder, Noga Therapeutics
abC Defghij	Board Member	N\A

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Apr. 15, 2024

R&D

abCDe

Seed

Jul. 01, 2021

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Services	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Last Updated:	abCDe
IVC Number:	abCDe